Bank of America’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Bank of America’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$252K	–	8624
2022 Q4	$252K	Hold	25,000	–	–	﹤0.01%	5793
2022 Q3	$248K	Hold	25,000	–	–	﹤0.01%	5854
2022 Q2	$248K	Sell	25,000 -141,523	-85%	-$1.39M	﹤0.01%	5934
2022 Q1	$1.64M	Hold	166,523	–	–	﹤0.01%	4785
2021 Q4	$1.64M	Hold	166,523	–	–	﹤0.01%	4761
2021 Q3	$1.62M	Hold	166,523	–	–	﹤0.01%	4636
2021 Q2	$1.61M	Buy	166,523 +25,000	+18%	+$243K	﹤0.01%	4498
2021 Q1	$1.38M	Buy	+141,523	New	+$1.37M	﹤0.01%	4554

Bank of America's BIOT Position: Q1 2023 in Review

Bank of America sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 25,000 shares — an estimated $252K sold.

Bank of America first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $1.64M in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Bank of America reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Bank of America sold 25,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $252K.
Bank of America first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Bank of America's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.64M in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.